| Primary |
| Acute Coronary Syndrome |
56.4% |
| Anticoagulant Therapy |
6.4% |
| Deep Vein Thrombosis |
6.4% |
| Acute Myocardial Infarction |
5.1% |
| Hypertension |
3.8% |
| Product Used For Unknown Indication |
3.8% |
| Coagulopathy |
2.6% |
| Drug Use For Unknown Indication |
2.6% |
| Pain |
2.6% |
| Thrombosis Prophylaxis |
2.6% |
| Angina Unstable |
1.3% |
| Anxiety |
1.3% |
| Arterial Thrombosis |
1.3% |
| Gastric Ulcer |
1.3% |
| Myocardial Infarction |
1.3% |
| Thrombosis |
1.3% |
|
| Catheter Related Complication |
31.5% |
| Coronary Artery Thrombosis |
13.0% |
| Drug Ineffective |
7.4% |
| Wound Secretion |
5.6% |
| Cerebrovascular Accident |
3.7% |
| Hypotension |
3.7% |
| Post Procedural Haemorrhage |
3.7% |
| Somnolence |
3.7% |
| Thrombosis |
3.7% |
| Vascular Pseudoaneurysm |
3.7% |
| Vomiting |
3.7% |
| Contusion |
1.9% |
| Electrocardiogram St Segment Depression |
1.9% |
| Electromechanical Dissociation |
1.9% |
| Embolism |
1.9% |
| Haemarthrosis |
1.9% |
| Haematoma |
1.9% |
| Haematuria |
1.9% |
| Haemorrhage |
1.9% |
| Haemorrhagic Stroke |
1.9% |
|
| Secondary |
| Thrombosis Prophylaxis |
14.3% |
| Acute Myocardial Infarction |
13.0% |
| Pulmonary Embolism |
13.0% |
| Adenocarcinoma |
7.8% |
| Deep Vein Thrombosis |
7.8% |
| Metastases To Lymph Nodes |
7.8% |
| Trousseau's Syndrome |
7.8% |
| Prophylaxis |
5.2% |
| Acute Coronary Syndrome |
3.9% |
| Malignant Atrophic Papulosis |
3.9% |
| Stent Placement |
3.9% |
| Vena Cava Thrombosis |
3.9% |
| Product Used For Unknown Indication |
2.6% |
| Renal Vein Thrombosis |
2.6% |
| Drug Use For Unknown Indication |
1.3% |
| Secondary Amyloidosis |
1.3% |
|
| Pneumonia |
20.0% |
| Subarachnoid Haemorrhage |
13.3% |
| Acute Generalised Exanthematous Pustulosis |
6.7% |
| Cerebrovascular Accident |
6.7% |
| Coma |
6.7% |
| Gastrointestinal Haemorrhage |
6.7% |
| Haematemesis |
6.7% |
| Post Procedural Haemorrhage |
6.7% |
| Thrombotic Thrombocytopenic Purpura |
6.7% |
| Type Iv Hypersensitivity Reaction |
6.7% |
| Unresponsive To Stimuli |
6.7% |
| Vena Cava Thrombosis |
6.7% |
|
| Concomitant |
| Product Used For Unknown Indication |
38.7% |
| Drug Use For Unknown Indication |
18.1% |
| Hiv Infection |
4.0% |
| Thrombosis Prophylaxis |
3.6% |
| Pain |
3.2% |
| Rheumatoid Arthritis |
3.2% |
| Acute Coronary Syndrome |
2.8% |
| Chronic Lymphocytic Leukaemia |
2.4% |
| Colon Cancer |
2.4% |
| Diabetes Mellitus |
2.4% |
| Diffuse Large B-cell Lymphoma |
2.4% |
| B-cell Lymphoma |
2.0% |
| Hypertension |
2.0% |
| Plasma Cell Myeloma |
2.0% |
| Pneumonia |
2.0% |
| Tuberculosis |
2.0% |
| Anxiety |
1.6% |
| Heparin-induced Thrombocytopenia |
1.6% |
| Prophylaxis |
1.6% |
| Pyrexia |
1.6% |
|
| Thrombocytopenia |
8.3% |
| Thrombosis |
8.3% |
| Vision Blurred |
8.3% |
| Intracranial Pressure Increased |
5.6% |
| No Adverse Event |
5.6% |
| Pneumonia |
5.6% |
| Prostate Cancer |
5.6% |
| Pyrexia |
5.6% |
| Sepsis |
5.6% |
| Systemic Lupus Erythematosus |
5.6% |
| Urosepsis |
5.6% |
| Vena Cava Thrombosis |
5.6% |
| Venous Occlusion |
5.6% |
| Cardiac Tamponade |
2.8% |
| Compartment Syndrome |
2.8% |
| Deep Vein Thrombosis |
2.8% |
| Drug Effect Delayed |
2.8% |
| Drug Intolerance |
2.8% |
| Drug Reaction With Eosinophilia And Systemic Symptoms |
2.8% |
| Enuresis |
2.8% |
|
